Xarelto Lawsuit Numbers Now Surpass 1,900 Cases

November 02, 2015 – – BloodThinnerHelp.com reports that the number of Xarelto lawsuits filed has now surpassed 1,900. This number is expected to continue to rise and to hit 2,000 in the near future. Xarelto, a newer form of blood thinner which entered the market in 2011, has been cited in these lawsuits to cause adverse health events, generally involving near fatal and even fatal uncontrollable bleeding episodes.

The blood thinner is considered extra dangerous due to the fact that it has no known antidote. If patients taking older forms of blood thinners became injured and bled, for example, doctors were able to administer a vitamin K treatment, which worked as an antidote for their blood thinner and counteracted its effects, allowing their blood to clot. Individuals using Xarelto do not have this option, as the drug doesn’t respond to vitamin K.

Many of the lawsuits filed are against manufacturer Janssen Pharmaceuticals, and its parent company, Johnson & Johnson. They are the first to manufacture a blood thinner that has a one pill a day, one-size-fits-all dosage. These factors, originally thought of as revolutionary and convenient, are now being questioned by individuals filing complaints. The drug is generally given to patients with atrial fibrillation, or who are recovering from knee and hip replacement surgeries.

Since the negative allegations regarding the drug have begun to surface, the U.S. Food and Drug Administration has also issued several warnings about Xarelto use despite its initial approval of the drug.

A study published earlier in the year by the British Medical Journal noted that there was a “twofold higher risk of bleeding with rivaroxaban [Xarelto] compared with warfarin.” Additionally, a 2013 study also indicated that patients treated with Xarelto were at a significantly increased risk for fatal gastrointestinal bleeding compared with those who used older versions of blood thinners such as warfarin.

Last year, the Journal of the American Medical Association published a study which also found that treatment with rivaroxaban (Xarelto) was associated with “severe, symptomatic liver injury.” This danger is not noted by manufacturers.

In the midst of these studies, individuals from across the nation are coming forward with their own personal stories and are filing lawsuits against Xarelto manufacturers. The most recent counts show that currently 1,600 Xarelto lawsuits have been filed federally and consolidated to form multidistrict litigation in Louisiana. Additionally, 300 cases are said to be involved in a mass tort action before a Pennsylvania court. These total cases, now numbering 1,900, are said to represent just the beginning of what is to come.

Attorney Marc Goldich is currently working hard to ensure that anyone who has experienced adverse side effects after using Xarelto has the ability to explore their legal options. He offers free consultations, and indicates that these individuals may be entitled to compensation.

For additional information concerning this press release or to ask questions, please contact Marc Goldich, Esq. at 866-435-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60005037